Diabetes. Type 2 diabetes mellitus with neurological complications
Conditions
Interventions
Intervention 1: Intervention group: All patients participating in the study are initially determined by the EMG-NCV device, the action voltage and nerve conduction speed of both their lower limbs. The
Sponsors
Yasouj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes who have symptoms related to peripheral neuropathy. Age between 30 and 70 years Be able to cooperate and communicate. Not having chronic diseases (cardiovascular, renal, and thyroid disorder) Not pregnant or breastfeeding. Not taking drugs that are effective in aggravating or alleviating neuropathy, such as tricyclic antidepressants, antipsychotics, anticonvulsants, and painkillers. Do not have other diseases such as vitamin B12 deficiency, stroke, etc., which lead to neuropathy. Based on the Michigan Diabetic Neuropathy scoring questionnaire, the patients should have moderate and severe severity of neuropathy Systolic blood pressure is higher than 110.
Exclusion criteria
Exclusion criteria: 1. Severe sensitivity to clonidine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diabetic neuropathy. Timepoint: Before and after the intervention. Method of measurement: Michigan Diabetic Neuropathy Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscular nervous system. Timepoint: Before and after the intervention. Method of measurement: -: EMG-NCV. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEshagh Moradi Sheibani
Yasouj University of Medical Sciences
Outcome results
None listed